ライフサイエンスコーパス: bucindolol

1 nt with the beta-blocker/sympatholytic agent bucindolol.

2 xperience greater sympatholytic effects from bucindolol.

3 rvival Trial (BEST; 1995-1999), of the 2707 (bucindolol=1353; placebo=1354) patients with heart failu

4 ease in plasma norepinephrine in response to bucindolol (-249+/-171 versus -35+/-277 pg/mL, P<0.05).

5 Bucindolol, a nonselective beta-receptor blocker, howeve

6 Moprolol and some bucindolol analogs appeared as conventional agonists, wh

7 ional agonists, whereas other alprenolol and bucindolol analogs lost all receptor interaction.

8 s and was predictive of outcomes in both the bucindolol and placebo treatment groups.

9 In contrast, bucindolol and xamoterol increased cAMP levels in a conc

10 In transfected cells, bucindolol antagonized agonist-stimulated cAMP, with a g

11 Gly-389 carriers had no clinical response to bucindolol compared with placebo.

12 Bucindolol exhibits approximately 60% of the beta-adrene

13 ihood-based method indicated that 18% of the bucindolol group but only 1% of the placebo group were a

14 owever, the Arg-389 homozygotes treated with bucindolol had an age-, sex-, and race-adjusted 38% redu

15 In BEST, a subset of patients treated with bucindolol had an increased risk of death as the result

16 Bucindolol has partial agonist properties in rat myocard

17 Bucindolol, however, significantly antagonized the respo

18 re assessed in a placebo-controlled trial of bucindolol in 1,040 HF patients.

19 d effectiveness of beta-blocker therapy with bucindolol in patients with HF enrolled in the Beta-Bloc

20 mias by the beta-blocker/sympatholytic agent bucindolol is influenced by genetic variation in adrener

21 tress echocardiography before treatment with bucindolol (n=41) or placebo (n=38).

22 l LVEF of 35% after 12 months, and effect of bucindolol on both outcomes were compared across HFREF s

23 d on one of three beta-blockers (carvedilol, bucindolol or metoprolol) and the dose was advanced to t

24 tes) who were randomized to the beta-blocker bucindolol or placebo in BEST and followed for mortality

25 phasic agonists (alprenolol, oxprenolol, and bucindolol), predictions based on ligand similarity and

26 Bucindolol prevents VT/VF in subjects with heart failure

27 ersely with change in LVEF after 3 months of bucindolol (r=-0.72, P<0.0001) and was the most signific

28 Bucindolol reduced VT/VF in beta(1)389 Arg homozygotes (

29 with heart failure, but one study assessing bucindolol reported a nonsignificant increase in mortali

30 ha(2c)322-325 polymorphism altered the VT/VF bucindolol response in beta1389 Gly carriers, with alpha

31 ZD 7114, xamoterol, and bucindolol significantly increased basal HR (DeltaHR: +1

32 nteraction between genotype and outcome with bucindolol that does not seem to occur with metoprolol o

33 To address this, we measured the ability of bucindolol to increase cAMP accumulation in human myocar

34 In the bucindolol-treated group but not in the placebo-treated

35 In the placebo-treated group but not in the bucindolol-treated group, marked norepinephrine increase

36 differ from a survival benefit reported for bucindolol-treated homozygous ADRB1 R389 individuals.

37 osis, improvement in LVEF, and the effect of bucindolol treatment differed significantly between subt

38 ociation class III/IV and LVEF < or =0.35 to bucindolol versus placebo.

39 The beta-blocker bucindolol was an inverse agonist in failing Arg, but no

40 In all genotypes bucindolol was associated with a lower incidence of VT/V

41 ol, alprenolol, bisoprolol, ICI 118,551, and bucindolol) was tested to prove the assay performance.